Covid-19’s disproportionate impact on Black, Hispanic, and indigenous groups has amplified pressure on health care leaders to address longstanding health inequities. Clinical trials and research have been identified as areas where historic barriers to inclusivity have significant negative downstream consequences. The data is clear that minority and rural populations are not represented in research in numbers that reflect the disease burden and prevalence. As part of our ongoing research on this topic, the Advisory Board convened 23 executives across five industry sectors for a workshop to discuss:
1) What principles and practices must the ecosystem revisit as we layer on a new goal—diversity—to an enterprise built to generate product safety and efficacy data?
2) Does our current value framework for clinical research impede adoption of best practices for promoting diverse patient enrollment?
This briefing contains five of the most important takeaways from this conversation as well as questions we recommend stakeholders ask as they undertake this important work.
For more than 40 years, we've helped executives and future leaders in health care work smarter and faster by providing provocative insights, actionable strategies, and practical tools to support execution.
With 40+ years of experience, a team of 250+ experts, and a network of 4,900+ member organizations that span the payer, provider, and supplier industries, we support life sciences firms’ commercial and medical leaders with research and educational resources that develop market strategy, enrich customer insight, and more.
Create your free account to access 2 resources each month, including the latest research and webinars.
You have 2 free members-only resources remaining this month remaining this month.
Never miss out on the latest innovative health care content tailored to you.